microDimensions, global provider of state-of-the-art digital pathology software and services, won Definiens as one of their customers. Definiens is the pioneer in Tissue Phenomics® solutions for diagnostics development and commercialization and was recently acquired by MedImmune, the biologics research and development arm of AstraZeneca.
As a new customer of microDimensions, Definiens will be combining microDimensions’ co-registration technology with their own technology to enhance the work of their internal research team in immuno-oncology. The goal is to automatically align immunohistochemically stained serial tissue sections with unprecedented speed and accuracy. This, for instance, enables the computation of spatially resolved, highly multiplexed readouts which are required to discover highly predictive diagnostic biomarkers for personalized cancer treatment.
“The co-registration functionality of microDimensions’ technology is unrivaled in terms of speed and accuracy,” says Dr. Günter Schmidt, Vice President Research at Definiens. “Using the cutting-edge algorithms of microDimensions incorporated into Definiens’ Tissue Phenomics technology will considerably accelerate our phene discovery process for immune-mediated cancer therapies.”
More information on the technology portfolio, services, and products of microDimensions can be found on micro-dimensions.com.
Meet microDimensions in person at the
- Digital Pathology Congress, 3-4 December 2015, London, UK, booth #19.
To schedule an appointment, please send an e-mail with your preferred date and time to sales@micro-dimensions.com.
You can also join microDimensions’ free webinar on volumetric histology. Register at micro-dimensions.com/webinars for one of the following dates:
- Monday, 17 August 2015, 8am PDT / 11am EDT / 17:00 CEST
- Wednesday, 30 September 2015, 10:00 CEST / 17:00 JST
- Tuesday, 10 November 2015, 9am PT / 12pm ET / 18:00 CET
About Definiens:
Definiens is the pioneering provider of Tissue Phenomics® solutions for biomarker and companion diagnostics development and commercialization. Definiens’ technology empowers smarter tissue-based diagnostics by leveraging quantitative tissue readouts and other big data sources. By enabling the development of powerful and precise assays for patient stratification and clinical trial enrollment, Definiens aims to dramatically improve patient outcomes. Definiens' Tissue Phenomics approach was awarded the 2013 Frost and Sullivan Company of the Year Award for Global Tissue Diagnostics and Pathology Imaging. For more information, please visit: www.definiens.com.
About microDimensions:
microDimensions develops and distributes software for microscopic image processing and analysis. Their solutions and services can be tailored to and seamlessly integrated into digital pathology workflows. microDimensions’ cutting-edge products Voloom®, Outspace™, and Zoom are the world’s fastest tools for convenient and accurate 3D histology reconstruction, stereology, and digital pathology viewing, respectively. They enable pharmaceutical and biotech companies to accelerate early drug testing and allow research organizations to gain new insights into cancer, multiple sclerosis, chronic infections, and other diseases.
Contact:
Dr. Marco Feuerstein
COO, microDimensions
pr@micro-dimensions.com
+49 89 1894253 34